I find it unconscionable that with the outstanding results of Rida in the endometral trials, that Merck hasn't leveraged off this and said SOMETHING about moving this forward to help patients with this dreaded condition.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.